Trial · NCT05346419
Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients
NCT05346419, Not applicable, Completed, Hospital Regional 1o de Octubre
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients. Trials, record NCT05346419. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05346419
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients
- NCT number
- NCT05346419
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 33 participants, actual
- Lead sponsor
- Hospital Regional 1o de Octubre
- Conditions
- Postmenopausal Osteoporosis, Hypovitaminosis D, Hyperparathyroidism
- Interventions
- Risedronate, Vitamin D
- First posted
- 2022-04-26
- Last updated
- 2022-04-26
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Remission of hyperparathyroidism | 6 months | Remission of hyperparathyroidism was considered when serum parathyroid hormone \[PTH\] values were below 45 pg/mL. |
| Primary | Remission of hypovitaminosis D | 6 months | Remission of hypovitaminosis D was considered when serum 25-hydroxy vitamin D \[25(OH)D\] was above 29 pg/ml. |
| Primary | Remission of osteopenia | 6 months | Osteopenia remission was considered when densitometry T-score values were below -1. |
| Primary | Remission of Osteoporosis | 6 months | Osteoporosis remission was considered when densitometry T-score values were below -2.4. |
| Secondary | Change from baseline serum calcium at 6 months | 6 months | Calcium was evaluated as a bone mineralization marker. |
| Secondary | Change from baseline serum phosphorus at 6 months | 6 months | Phosphorus was evaluated as a bone mineralization marker. |
| Secondary | Change from baseline urinary calcium at 6 months | 6 months | Urinary calcium was evaluated as an indirect marker of bone demineralization. |
| Secondary | Change from bone resorption biomarker at 6 months | 6 months | Alkaline Phosphatase was evaluated as a bone resorption biomarker. |
| Secondary | Fracture Risk Assessment Tool (FRAX®) for hip fracture | 6 months | Fracture Risk Assessment Tool (FRAX®) for hip fracture was used to determine the 10-year probability of hip fracture. When the predicted risk was greater than 3% was considered a high risk for hip fracture, and when it was lower than 3%, it was considered a low risk for hip fracture. |
| Secondary | Fracture Risk Assessment Tool for major osteoporotic fracture (FRAX® Mo) | 6 months | Fracture Risk Assessment Tool for major osteoporotic fracture (FRAX® Mo) was used to determine the 10-year probability of major osteoporotic fracture (clinical spine, forearm, hip or shoulder fracture). When the predicted risk was greater than 20% was considered a high risk for major osteoporotic fracture, and when it was lower than 20%, it was considered a low risk of major osteoporotic fracture. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers31
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05346419
GET https://conductscience.org/api/trials/v1/NCT05346419/papers?page=2